Alecensa Capsule
Product Images NDC 50242-130

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Alecensa (NDC 50242-130). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Genentech, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Alecensa 01)

Chemical structure of ALECTINIB HYDROCHLORIDE, showing its molecular arrangement including multiple ring systems and functional groups as part of the compound's structure.*

FDA Label Image

Figure 1 (Alecensa 02)

Kaplan-Meier curve charting progression-free survival (%) over months (Day 1 to 27) for two drugs, Alectinib and Crizotinib. The graph shows survival rates with Alectinib higher than Crizotinib over time. Below the graph, a table lists the number of patients at risk for each drug at various time points.*

FDA Label Image

Alecensa 03

Label for Alecensa 150 mg capsules containing alectinib, an oral prescription drug by Genentech, Inc. The label states each capsule contains 150 mg of alectinib (equivalent to 161.33 mg alectinib HCl). The package size is 240 capsules and the product NDC is 50242-130-01.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.